Bioheng is rebranding to Imviva Biotech to better reflect our global positioning and expansion.

Bioheng Therapeutics is a clinical-stage company focused on allogeneic "off-the-shelf" universal CAR-T therapies. Founded in 2017, we aim to develop the world’s leading allogeneic cell therapy platforms and products to address some of the most challenging unmet needs.

In February 2025, our CD7-targeted UCAR-T, CTD402, received Investigational New Drug (IND) approval from the U.S. FDA for the treatment of T-ALL/LBL.This product is based on Bioheng's novel and proprietary UCAR-T technology platform - ANSWER®. We are progressing the global clinical trial for this promising pipeline.

Built upon our ANSWER® platform, we are actively developing multiple UCAR-T pipelines. These programs have demonstrated robust and extended allogeneic CAR-T persistence, showing strong potential in both oncology and autoimmune indications.

We are always striving to meet these unmet needs.

Imviva Biotech

The Boston office focuses on financial leadership and strategy, driving fiscal growth and operational excellence.

Boston

Lu Han

This department focuses on strategic partnerships, acquisitions, and overall business growth initiatives.

Corporate Development

This department oversees the quality management processes to ensure products meet required standards and compliance.

Imviva Biotech

Org chart

Teams

Corporate Development

Quality Assurance

Offices

Imviva Biotech

Org chart

Teams

Corporate Development

Quality Assurance

Offices

Related companies